Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution

Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday.

Michael Cherny has given his Hold rating due to a combination of factors reflecting Quest Diagnostics’ recent performance and future expectations. Cherny acknowledges the company’s strong earnings report, noting that despite initial concerns such as weather disruptions, Quest Diagnostics delivered a solid financial performance with impressive gross and adjusted EBIT margins. The margins are particularly noteworthy given the potential dilution effects from the Haystack acquisition. Additionally, the earnings per share (EPS) guidance was raised, albeit by a smaller margin than the actual earnings beat, which still contributes to a positive outlook for the company.

Cherny also points to several key drivers to watch for in Quest Diagnostics’ future performance, which influence the Hold rating. These include the health of the price/volume mix, operational improvements from the Invigorate program, and the financial impact of the Haystack integration. Furthermore, the company’s capital deployment strategies, including hospital partnerships and technological advancements, will be determinant factors. While the company shows solid fundamentals, these considerations suggest a cautious approach, leading to Cherny’s Hold rating rather than a more bullish Buy or bearish Sell recommendation.

In another report released yesterday, Barclays also maintained a Hold rating on the stock with a $144.00 price target.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DGX in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Quest Diagnostics (DGX) Company Description:

Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.